Panelists discuss how BTK inhibitors represent a promising new oral therapy class that could address both inflammatory and ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech ...

Researches at the University of Cincinnati's Gardner Neuroscience Institute could have discovered a new oral treatment that ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of ...

Dr. Simrit Parmar, a Northwestern University-trained oncologist and research scientist, launched Cellenkos Inc., in 2016 to accelerate the clinical development of "T regulatory cell" therapies for the ...

YORK dad Sid Gornall, whose son was diagnosed with mitochondrial disease has welcomed news of a medical breakthrough.

Panelists discuss how payers can evaluate BTK inhibitors by considering specific MS phenotypes and FDA indications rather ...

People with multiple sclerosis (MS) may have slightly shorter-than-average life spans, depending on disease severity, ...

But if the results are even close to what’s been achieved in the lab and swine work, the device could alter the treatment path for an all-too-common, all-too-serious medical issue.

Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are born with it and much fewer boys.